Comparative Pharmacology
Head-to-head clinical analysis: QUIBRON T versus TRUPHYLLINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QUIBRON T versus TRUPHYLLINE.
QUIBRON-T vs TRUPHYLLINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Quibron-T (theophylline) inhibits phosphodiesterase, increasing intracellular cAMP in airway smooth muscle and inflammatory cells, leading to bronchodilation and anti-inflammatory effects. It also antagonizes adenosine receptors and enhances respiratory drive.
Truphylline is a xanthine derivative that inhibits phosphodiesterase (PDE) and blocks adenosine receptors, leading to bronchodilation, increased respiratory drive, and anti-inflammatory effects.
Oral: 200-400 mg every 6-8 hours; sustained-release: 200-600 mg every 12 hours.
Aminophylline 5-6 mg/kg IV loading dose over 20-30 minutes, then 0.5-0.7 mg/kg/h continuous IV infusion; theophylline 300-600 mg PO daily divided q6-12h, titrated to serum theophylline level of 5-15 mcg/mL.
None Documented
None Documented
Terminal elimination half-life: 7-9 hours in nonsmoking adults; prolonged in hepatic cirrhosis (up to 30 hours) or heart failure; shorter in smokers (4-5 hours) due to enzyme induction.
Terminal half-life: adults 6-8 hours, children 3-5 hours, neonates 24+ hours. Prolonged in hepatic or cardiac impairment.
Renal: 70% as metabolites (1,3-dimethyluric acid, 3-methylxanthine, and 1-methyluric acid) and 10% as unchanged drug in adults; biliary/fecal: minimal, <5%.
Renal excretion of unchanged drug (80-90%) and metabolites; biliary/fecal elimination <10%.
Category C
Category C
Xanthine Bronchodilator
Xanthine Bronchodilator